|
|||||
|
|
Regulatory benefit–risk assessment of oncology drugs: A systematic review of FDA and EMA approvals |
|
| Affiliation: | 1. Biostatistics and Research Decision Sciences (BARDS), Department of Epidemiology, Merck & Co., Rahway, NJ, USA;2. Evidera, Bethesda, MD, USA;3. BARDS HTA Statistics, MSD, Zurich, Switzerland;4. Clinical Safety and Risk Management, Merck & Co., Rahway, NJ, USA |
| Abstract: | |
| Keywords: | regulatory benefit–risk assessment oncology drugs |
| 本文献已被 ScienceDirect 等数据库收录！ | |